Desloratadine

Drug Profile

Desloratadine

Alternative Names: Aerius; Allex; Azomyr; Clarinex; Clarinex Reditabs; Clarinex-D 12 Hour; DCL; Decarboethoxyloratadine; Desalex; Descarboethoxyloratadine; Di Heng Sai; MK-4117; Neoclarityn; Opulis; SCH-34117

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Sepracor
  • Developer Merck & Co
  • Class Antiallergics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis; Urticaria
  • Registered Atopic dermatitis; Dermatitis; Pruritus
  • Discontinued Asthma

Most Recent Events

  • 28 Sep 2016 Registered for Atopic dermatitis, Dermatitis, Perennial alllergic rhinitis, Pruritus, Urticaria in Japan (PO)
  • 11 Jul 2016 Kyorin Pharmaceuticals and Kaken Pharmaceuticals agree to co-promote desloratadine in Japan
  • 13 May 2016 Efficacy and safety data from a phase III trial in Urticaria presented at the Conference of the American Thoracic Society (ATS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top